RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

The flu virus is lingering in Arizona and the season has been vicious. Pediatric flu deaths reached the highest level in ...

The U.S. Food and Drug Administration has approved Merck's Enflonsia, a treatment to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The company said ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

RSV is responsible for around 1 lakh deaths, over 3.6 million hospitalisations in children under age of 5 every year, ...

but a decline is anticipated soon in an infection that most commonly afflicts children — respiratory syncytial virus, the Pima County Health Department says. The infection commonly referred to ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...